Cite
MacDonald GC, Rasamoelisolo M, Entwistle J, et al. A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck. Drug Des Devel Ther. 2009;2:105-14doi: 10.2147/dddt.s3442.
MacDonald, G. C., Rasamoelisolo, M., Entwistle, J., Cizeau, J., Bosc, D., Cuthbert, W., Kowalski, M., Spearman, M., & Glover, N. (2009). A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck. Drug design, development and therapy, 2105-14. https://doi.org/10.2147/dddt.s3442
MacDonald, Glen C, et al. "A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck." Drug design, development and therapy vol. 2 (2009): 105-14. doi: https://doi.org/10.2147/dddt.s3442
MacDonald GC, Rasamoelisolo M, Entwistle J, Cizeau J, Bosc D, Cuthbert W, Kowalski M, Spearman M, Glover N. A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck. Drug Des Devel Ther. 2009 Feb 06;2:105-14. doi: 10.2147/dddt.s3442. PMID: 19920898; PMCID: PMC2761172.
Copy
Download .nbib